Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying Both Ligand and SiRNA

Overview

Journal Sci Rep

Specialty Science

Date 2015 Jul 4

PMID 26137913

Citations 61

Authors

Daxiang Cui

Chunlei Zhang

Bing Liu

Yi Shu

Tong Du

Dan Shu

Kan Wang

Fangping Dai

Yanlei Liu

Chao Li

Fei Pan

Yuming Yang

Jian Ni

Hui Li

Beate Brand-Saberi

Peixuan Guo

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is the second leading cause of cancer-related death worldwide. RNA nanotechnology has recently emerged as an important field due to recent finding of its high thermodynamic stability, favorable and distinctive in vivo attributes. Here we reported the use of the thermostable three-way junction (3WJ) of bacteriophage phi29 motor pRNA to escort folic acid, a fluorescent image marker and BRCAA1 siRNA for targeting, imaging, delivery, gene silencing and regression of gastric cancer in animal models. In vitro assay revealed that the RNA nanoparticles specifically bind to gastric cancer cells, and knock-down the BRCAA1 gene. Apoptosis of gastric cancer cells was observed. Animal trials confirmed that these RNA nanoparticles could be used to image gastric cancer in vivo, while showing little accumulation in crucial organs and tissues. The volume of gastric tumors noticeably decreased during the course of treatment. No damage to important organs by RNA nanoparticles was detectible. All the results indicated that this novel RNA nanotechnology can overcome conventional cancer therapeutic limitations and opens new opportunities for specific delivery of therapeutics to stomach cancer without damaging normal cells and tissues, reduce the toxicity and side effect, improve the therapeutic effect, and exhibit great potential in clinical tumor therapy.

Citing Articles

Investigating the potential application of organic and non-organic nanoparticles for gastric cancer treatment: An evidence-based review.

Moradifar N, Moayyedkazemi A, Mohammadi H, Ahmadi Somaghian S, Raziani Y Arch Razi Inst. 2024; 79(2):264-271.

PMID: 39463705 PMC: 11512170. DOI: 10.32592/ARI.2024.79.2.264.

Therapeutic applications of RNA nanostructures.

Yip T, Qi X, Yan H, Chang Y RSC Adv. 2024; 14(39):28807-28821.

PMID: 39263430 PMC: 11387945. DOI: 10.1039/d4ra03823a.

and Evaluation of the Pathology and Safety Aspects of Three- and Four-Way Junction RNA Nanoparticles.

Jin K, Liao Y, Cheng T, Li X, Lee W, Pi F Mol Pharm. 2024; 21(2):718-728.

PMID: 38214504 PMC: 10976369. DOI: 10.1021/acs.molpharmaceut.3c00845.

RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity.

Li X, Jin K, Cheng T, Liao Y, Lee W, Bhullar A Biomaterials. 2024; 305:122432.

PMID: 38176263 PMC: 10994150. DOI: 10.1016/j.biomaterials.2023.122432.

3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 Macrophages Target BMSCs to Promote the Healing of Bone Fractures.

Shou J, Li S, Shi W, Zhang S, Zeng Z, Guo Z Stem Cells Transl Med. 2023; 12(11):758-774.

PMID: 37740533 PMC: 10630079. DOI: 10.1093/stcltm/szad052.

References

Rychahou P, Haque F, Shu Y, Zaytseva Y, Weiss H, Lee E . Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. ACS Nano. 2015; 9(2):1108-16. PMC: 4613746. DOI: 10.1021/acsnano.5b00067. View

Huang P, Xu C, Lin J, Wang C, Wang X, Zhang C . Folic Acid-conjugated Graphene Oxide loaded with Photosensitizers for Targeting Photodynamic Therapy. Theranostics. 2011; 1:240-50. PMC: 3092447. DOI: 10.7150/thno/v01p0240. View

Shi J, Zhang H, Wang L, Li L, Wang H, Wang Z . PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor. Biomaterials. 2012; 34(1):251-61. DOI: 10.1016/j.biomaterials.2012.09.039. View

Yang W, Raufi A, Klempner S . Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 2014; 1846(1):232-7. DOI: 10.1016/j.bbcan.2014.05.003. View

Shu D, Moll W, Deng Z, Mao C, Guo P . Bottom-up Assembly of RNA Arrays and Superstructures as Potential Parts in Nanotechnology. Nano Lett. 2010; 4(9):1717-23. PMC: 3010238. DOI: 10.1021/nl0494497. View

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9. DOI: 10.1056/NEJMoa001999. View

Lee T, Haque F, Shu D, Yoo J, Li H, Yokel R . RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget. 2015; 6(17):14766-76. PMC: 4558114. DOI: 10.18632/oncotarget.3632. View

Gao W, Xiang B, Meng T, Liu F, Qi X . Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials. 2013; 34(16):4137-4149. DOI: 10.1016/j.biomaterials.2013.02.014. View

Takahashi T, Saikawa Y, Kitagawa Y . Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013; 5(1):48-63. PMC: 3730304. DOI: 10.3390/cancers5010048. View

10.

Guo P . The emerging field of RNA nanotechnology. Nat Nanotechnol. 2010; 5(12):833-42. PMC: 3149862. DOI: 10.1038/nnano.2010.231. View

11.

Wang Z, Ruan J, Cui D . Advances and prospect of nanotechnology in stem cells. Nanoscale Res Lett. 2010; 4(7):593-605. PMC: 2894000. DOI: 10.1007/s11671-009-9292-z. View

12.

Zhang Y, Gao G, Liu H, Fu H, Fan J, Wang K . Identification of volatile biomarkers of gastric cancer cells and ultrasensitive electrochemical detection based on sensing interface of Au-Ag alloy coated MWCNTs. Theranostics. 2014; 4(2):154-62. PMC: 3900800. DOI: 10.7150/thno.7560. View

13.

Abdelmawla S, Guo S, Zhang L, Pulukuri S, Patankar P, Conley P . Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther. 2011; 19(7):1312-22. PMC: 3129564. DOI: 10.1038/mt.2011.35. View

14.

Chen F, Huang P, Zhu Y, Wu J, Zhang C, Cui D . The photoluminescence, drug delivery and imaging properties of multifunctional Eu3+/Gd3+ dual-doped hydroxyapatite nanorods. Biomaterials. 2011; 32(34):9031-9. DOI: 10.1016/j.biomaterials.2011.08.032. View

15.

Khisamutdinov E, Li H, Jasinski D, Chen J, Fu J, Guo P . Enhancing immunomodulation on innate immunity by shape transition among RNA triangle, square and pentagon nanovehicles. Nucleic Acids Res. 2014; 42(15):9996-10004. PMC: 4150753. DOI: 10.1093/nar/gku516. View

16.

Teng L, Xie J, Teng L, Lee R . Clinical translation of folate receptor-targeted therapeutics. Expert Opin Drug Deliv. 2012; 9(8):901-8. DOI: 10.1517/17425247.2012.694863. View

17.

Guo P, Haque F, Hallahan B, Reif R, Li H . Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther. 2012; 22(4):226-45. PMC: 3426230. DOI: 10.1089/nat.2012.0350. View

18.

Jasinski D, Khisamutdinov E, Lyubchenko Y, Guo P . Physicochemically tunable polyfunctionalized RNA square architecture with fluorogenic and ribozymatic properties. ACS Nano. 2014; 8(8):7620-9. PMC: 4148160. DOI: 10.1021/nn502160s. View

19.

Huang P, Bao L, Zhang C, Lin J, Luo T, Yang D . Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials. 2011; 32(36):9796-809. DOI: 10.1016/j.biomaterials.2011.08.086. View

20.

Afonin K, Grabow W, Walker F, Bindewald E, Dobrovolskaia M, Shapiro B . Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat Protoc. 2011; 6(12):2022-34. PMC: 3498981. DOI: 10.1038/nprot.2011.418. View